Biogen Idec Inc. | Cash Flow

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,862
2,942
3,593
3,696
2,670
4,474
Depreciation, Depletion & Amortization
532
637
600
683
1,081
651
Other Funds
69
79
4
29
454
555
Funds from Operations
2,258
3,426
4,292
4,449
4,316
5,788
Changes in Working Capital
87
484
576
73
235
400
Net Operating Cash Flow
2,345
2,942
3,716
4,522
4,551
6,188
Capital Expenditures
3,509
288
643
728
1,843
Purchase/Sale of Investments
1,912
864
2,802
534
211
Net Investing Cash Flow
1,605
1,543
4,554
2,485
2,963
Issuance/Reduction of Debt, Net
452
3
5,928
3
561
Net Financing Cash Flow
717
756
986
988
2,380
Net Change in Cash
32
602
103
1,019
753
Free Cash Flow
2,099
2,654
3,073
3,906
3,684
Deferred Taxes & Investment Tax Credit
245
308
146
175
92
108
Net Assets from Acquisitions
15
-
199
-
-
Other Sources
7
-
-
-
-
Change in Capital Stock
334
832
4,946
956
1,365
Exchange Rate Effect
8
41
46
31
39
Other Uses
-
391
910
1,223
1,331

About Biogen Idec

View Profile
Address
225 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.biogen.com
Updated 07/08/2019
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.